PMID- 35603648
OWN - NLM
STAT- MEDLINE
DCOM- 20220524
LR  - 20220524
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 38
IP  - 5
DP  - 2022 May
TI  - [Saxagliptin alleviates kidney injury in diabetic rats by down-regulating the 
      expression of mammalian target of rapamycin (mTOR)].
PG  - 406-411
AB  - Objective To investigate the effect of saxagliptin (Sax) against kidney injury in 
      diabetic rats and its mechanisms. Methods SD male rats were fed for 2 weeks, 
      among which 14 rats were selected randomly and given intraperitoneal injection of 
      streptozotocin (STZ) to establish the type 2 diabetes mellitus (T2DM) model, and 
      then were randomly divided into T2DM group and Sax group after the model was 
      successfully established; 6 rats were selected as normal control (NC) group 
      randomly. The rats of Sax group were given the saxagliptin solution. The rats of 
      NC and T2DM groups were injected with the same amount of sodium carboxymethyl 
      cellulose solution. After 8 weeks of continuous gastric administration, the rats 
      were sacrificed and their blood and kidney tissues were collected. Glucose (G1u), 
      albumin (ALB), aspartate transaminase (AST), alanine transaminase (ALT), serum 
      creatinine (Scr), blood urea nitrogen (BUN), uric acid (UA), serum total 
      cholesterol (TC), triglycerides (TG) were detected by automatic biochemical 
      analyzer. HE, PAS, Masson staining and transmission electron microscopy were 
      performed to observe the morphological changes of renal. Immunohistochemical 
      staining was used to detect the protein expression level of mammalian target of 
      rapamycin (mTOR), interleukin 1 (IL-1), IL-6, tumor necrosis factor alpha (TNF-alpha) in 
      renal tissues. Results Compared with the NC group, the levels of biochemical 
      indicators such as G1u, ALB, AST, ALT, Scr, BUN, UA, TC, and TG showed 
      significant increase; the number of glomerular mesangial cells also increased, 
      and the mesangial matrix hyperplasia, mTOR, IL-1, IL-6, TNF-alpha protein expression 
      levels exhibited significant increase in T2DM group. Compared with T2DM group, 
      Sax group showed decreased levels of biochemical indicators such as G1u, ALB, 
      AST, ALT, Scr, BUN, UA, TC, and TG and improved renal pathological damage 
      performance, together with a profound reduction in mTOR, IL-1, IL-6, TNF-alpha 
      protein expression level. Conclusion Sax may suppress inflammatory response and 
      reduce renal injury in diabetic rats by down-regulating mTOR expression.
FAU - Ni, Wenjing
AU  - Ni W
AD  - Department of Nephrology, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu 233000, China.
FAU - Pan, Yan
AU  - Pan Y
AD  - Department of Nephrology, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu 233000, China.
FAU - Yang, Huijuan
AU  - Yang H
AD  - Department of Nephrology, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu 233000, China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Nephrology, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu 233000, China.
FAU - Sun, Yan
AU  - Sun Y
AD  - School of Clinical Medicine, Bengbu Medical College, Bengbu 233000, China.
FAU - Xu, Yu
AU  - Xu Y
AD  - School of Life Science, Bengbu Medical College, Bengbu 233000, China.
FAU - Chen, Weidong
AU  - Chen W
AD  - Department of Nephrology, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu 233000, China. *Corresponding author, E-mail: cwd2012@163.com.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (Dipeptides)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9GB927LAJW (saxagliptin)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - PJY633525U (Adamantane)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adamantane/analogs & derivatives
MH  - Animals
MH  - *Diabetes Mellitus, Experimental/complications/drug therapy
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Dipeptides
MH  - Interleukin-1/metabolism
MH  - Interleukin-6/metabolism
MH  - Kidney/pathology
MH  - Male
MH  - Mammals
MH  - Rats
MH  - Sirolimus/pharmacology
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2022/05/24 06:00
MHDA- 2022/05/25 06:00
CRDT- 2022/05/23 06:17
PHST- 2022/05/23 06:17 [entrez]
PHST- 2022/05/24 06:00 [pubmed]
PHST- 2022/05/25 06:00 [medline]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2022 May;38(5):406-411.